Market Access

An NEJM study explores how this loss—following Medicaid disenrollment—affects beneficiaries.

Andrew Witty resigns due to personal reasons, as Stephen Hemsley, chairman and former chief executive, will assume the position.

Ways to reimagine pharma’s operating model and KPIs for commercial success in an AI-driven future.

A seminar shares key observations and learnings from the first round of direct price negotiations.

A session dives into the trends surrounding specialty drugs and therapies, along with providing an overview of the drug development landscape.

The interchangeability designation for Yuflyma, a biosimilar to Humira, may help to improve patient access and reduce costs.

The key strategies for reducing or eliminating post-prescription abandonment.

A look at the prevailing factors impacting treatment access in 2025.

How pharma manufacturers can steadily navigate GTN components and complexities when planning pharmacy benefit reimbursement.

Respective industry and government agendas could significantly reshape the US prescription drug market.

How data-driven insights can help pharma companies balance their revenue management and innovation strategies—including resource allocation, pricing, and market access.

Jen Butler, chief commercial officer, Pleio, discusses how the company’s GoodStart programs help patients navigate specialty pharmacies.

Jonathan James, CEO, Hope Charities, discusses how, despite policy advancements, millions of people still face barriers to healthcare access.

A roundtable explores how patient access needs are being measured, while also discussing the value of affordability in decision-making.

The partnership focuses on enhancing the patient experience by providing greater affordability and access to specialty meds.

NovoCare will offer the GLP-1 injection to cash-paying patients for a discounted $499 per month.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Geoffrey Joyce, PhD, director of health policy at the Leonard D. Schaeffer Center for Health Policy & Economics at USC, describes how PBMs financially benefit from generics, and why a completely open generic market powered by cash would be beneficial.

The injection for the treatment of psoriatic arthritis—among other indications—is a biosimilar to Stelara.

Digging a little deeper into the drug class phenomenon reveals some interesting takeaways on a smaller subgroup of users.

How chain and local closures are impacting healthcare access.

Finding the optimal balance in pharmacy benefit manager reform.

A look at the actionable steps needed to elicit change.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Ed Schoonveld value & access advisor for Schoonveld Advisory and author of The Price of Global Health, previews his upcoming February column.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Ed Schoonveld, value & access advisor for Schoonveld Advisory and author of The Price of Global Health, comments on the future implications of the latest CMS drug price negotiations.

A cross-sectional study investigates the impact of Dobbs v Jackson’s Women’s Health Organization on national support and personal interest.

What factors influence their likelihood of receiving this form of obesity treatment?

A forum intended for HCPs, policy experts, and industry leaders addresses pressing obstacles facing this sector of the industry today.

A panel examines the gross-to-net bubble across various product mixes, how pricing impacts market access, and more.

Kevin O’Meara discusses how patient service teams influence adherence from Direct-to-Patient models.

Kevin O’Meara discusses Patient-Cetric 3.0 breakout session and the challenges of drug manufactures implementing Direct-to-Patient models.